Posted by Michael Wonder on 04 Aug 2022
TGA says go to BioMarin for Voxzogo
4 August 2022 - Vosoritide is a modified type C natriuretic peptide.
Voxzogo has been approved for the treatment of achondroplasia in patients 2 years of age and older whose epiphyses are not closed. The diagnosis of achondroplasia should be confirmed by appropriate genetic testing.
